Graduate Program in Adult Health - Federal University of Maranhão-UFMA, Rua Munim, n° 001, Condomínio Vitré, BL 08 AP 304, São Luis, MA, CEP: 65070-017, Brazil.
Graduate Program in Adult Health - Federal University of Maranhão-UFMA, Av. dos Portugueses, 1966 - Vila Bacanga, São Luís, MA, CEP: 65065-545, Brazil.
Support Care Cancer. 2021 Dec;29(12):7171-7182. doi: 10.1007/s00520-021-06242-5. Epub 2021 Jun 19.
The objective of the present study was to carry out a systematic review with a meta-analysis to assess evidence about the use of guarana fruit to manage fatigue in cancer patients.
The data were extracted from the EMBASE, Scopus, MEDLINE, CENTRAL, and CINAHL databases, in any language, using the descriptors "neoplasms" and "Paullinia" or "guarana powder" and "placebos" and "fatigue". Searches were also conducted to identify any grey literature. Clinical studies with patients who presented cancer-related fatigue as a primary outcome and who used guarana as a dietary supplement were included. The risk of bias in randomized clinical trials was analyzed according to the Cochrane recommendations. The quality of the evidence was assessed using the GRADE system. For studies with the same types of tumors and treatments, meta-analysis was also conducted.
A total of 383 studies were found and, of these, seven were included in the review, for a total of 427 cancer patients. The instruments used to analyze fatigue were the Brief Fatigue Inventory (BFI), the Chalder Fatigue Scale, the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE), and the Piper Scale. Some studies presented a low risk of bias for all the categories. Meta-analysis was conducted for three studies about breast cancer, which presented sufficient data. The use of guarana did not reduce cancer-related fatigue compared with placebo groups (mean of - 0.02 [95% CI - 1.54, 1.50]; p = 0.98) and the quality of evidence according to GRADE was very low.
Dietary supplements are used to improve cancer-related fatigue. The results of this review showed that the use of guarana was not superior to the placebo groups, pointing to the need for further studies with better methodological quality.
本研究旨在进行系统评价和荟萃分析，评估瓜拉那果实用于管理癌症患者疲劳的证据。
数据从 EMBASE、Scopus、MEDLINE、CENTRAL 和 CINAHL 数据库中提取，使用“肿瘤”和“Paullinia”或“瓜拉那粉”和“安慰剂”和“疲劳”的描述符，以任何语言进行检索。还进行了灰色文献的搜索。纳入的临床研究为以癌症相关疲劳为主要结局且使用瓜拉那作为膳食补充剂的患者。根据 Cochrane 建议分析随机临床试验的偏倚风险。使用 GRADE 系统评估证据质量。对于具有相同类型肿瘤和治疗方法的研究，也进行了荟萃分析。
共发现 383 项研究，其中 7 项纳入综述，共纳入 427 名癌症患者。用于分析疲劳的仪器是简要疲劳量表（BFI）、Chalder 疲劳量表、慢性疾病治疗功能评估-疲劳量表（FACIT-FATIGUE）和 Piper 量表。一些研究在所有类别中均存在低偏倚风险。对三项关于乳腺癌的研究进行了荟萃分析，这些研究提供了足够的数据。与安慰剂组相比，瓜拉那的使用并未降低癌症相关疲劳（平均差值-0.02 [95% CI-1.54, 1.50]；p=0.98），根据 GRADE 评估的证据质量非常低。
膳食补充剂用于改善癌症相关疲劳。本综述结果表明，瓜拉那的使用并不优于安慰剂组，表明需要进一步进行方法学质量更高的研究。
